BidaskClub upgraded shares of TG Therapeutics, Inc. (NASDAQ:TGTX) from a sell rating to a hold rating in a research report released on Thursday morning.

TGTX has been the topic of several other reports. FBR & Co reaffirmed a buy rating on shares of TG Therapeutics in a research note on Monday, May 1st. Zacks Investment Research downgraded shares of TG Therapeutics from a hold rating to a sell rating in a research note on Tuesday, May 16th. Jefferies Group LLC reaffirmed a buy rating and set a $23.00 target price on shares of TG Therapeutics in a research note on Monday, June 5th. Finally, ValuEngine raised shares of TG Therapeutics from a sell rating to a hold rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $25.40.

Shares of TG Therapeutics (NASDAQ TGTX) opened at 11.45 on Thursday. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35. The firm’s 50-day moving average price is $11.09 and its 200 day moving average price is $10.47. The company’s market capitalization is $713.45 million.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. On average, equities analysts forecast that TG Therapeutics will post ($1.84) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/28/tg-therapeutics-inc-tgtx-lifted-to-hold-at-bidaskclub.html.

In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $11.09, for a total value of $665,133.84. Following the sale, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at approximately $5,295,075.76. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 16.70% of the company’s stock.

Large investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its stake in shares of TG Therapeutics by 1.9% in the second quarter. California State Teachers Retirement System now owns 85,935 shares of the biopharmaceutical company’s stock worth $864,000 after buying an additional 1,600 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of TG Therapeutics by 67.1% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 49,146 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 19,740 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of TG Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 36,754 shares of the biopharmaceutical company’s stock worth $370,000 after buying an additional 7,630 shares in the last quarter. State Street Corp increased its stake in shares of TG Therapeutics by 274.4% in the second quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock worth $26,515,000 after buying an additional 1,933,896 shares in the last quarter. Finally, Voya Investment Management LLC increased its stake in shares of TG Therapeutics by 40.2% in the second quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 6,463 shares in the last quarter. 46.53% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.